(Q33400837)

English

The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

liver cirrhosis

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

object named as

Thomas Yau

13

0 references

author name string

Joanne Chiu

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yuen Fong Tang

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tzy-Jyun Yao

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ashley Wong

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hilda Wong

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Roland Leung

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pierre Chan

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tan To Cheung

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Albert C Chan

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Roberta Pang

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sheung-Tat Fan

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ronnie Poon

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

19 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

118

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

5293-5301

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27543

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27543

21 January 2018

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27543

21 January 2018

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27543

21 January 2018

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27543

21 January 2018

Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27543

21 January 2018

Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27543

21 January 2018

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27543

21 January 2018

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27543

21 January 2018

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27543

21 January 2018

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27543

21 January 2018

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27543

21 January 2018

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27543

21 January 2018

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27543

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.27543

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33400837&oldid=1644582609"